CATX (Perspective Therapeutics) Tax Provision : $2.10 Mil (TTM As of Dec. 2024)

View and export this data going back to 2005. Start your Free Trial

What is Perspective Therapeutics Tax Provision?

Perspective Therapeutics's tax provision for the three months ended in Dec. 2024 was $2.10 Mil. Its tax provision for the trailing twelve months (TTM) ended in Dec. 2024 was $2.10 Mil.

Perspective Therapeutics Tax Provision Historical Data

The historical data trend for Perspective Therapeutics's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Perspective Therapeutics Tax Provision Chart

Perspective Therapeutics Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Dec23

Dec24

Tax Provision

Get a 7-Day Free Trial

2.65

2.10

Perspective Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Tax Provision	Get a 7-Day Free Trial															-7.85	-	-	-	2.10

Perspective Therapeutics Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.10 Mil.

Perspective Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Perspective Therapeutics Inc (AMEX:CATX) » Definitions » Tax Provision

Comparable Companies

Traded in Other Exchanges

AAJ0:Germany AAJ0:Germany

Address

2401 Elliott Avenue, Suite 320, Seattle, WA, USA, 98121

Website

https://www.perspectivetherapeutics.com

Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.

Executives

Williamson Robert F Iii	director	140 LASALLE AVENUE, PIEDMONT CA 94610
Lori A Woods	officer: Vice President	350 HILLS STREET, SUITE 106, RICHLAND WA 99354
Johan M. Spoor	director, officer: CEO	500 BOYLSTON STREET, SUITE 1600, BOSTON MA 02116
Heidi Henson	director	2173 SALK AVENUE, SUITE 250, PMB#052, CARLSBAD CA 92008
Jonathan Robert Hunt	officer: Chief Financial Officer	350 HILLS STREET, SUITE 106, RICHLAND WA 99354
Markus Puhlmann	officer: Chief Medical Officer	350 HILLS STREET, SUITE 106, RICHLAND WA 99354
Frank Morich	director	40 GUEST STREET, BOSTON MA 02135
Mark John Austin	officer: Controller/Prin Fin&Acct Offic	350 HILLS ST, STE 106, RICHLAND WA 99354
Michael Krachon	officer: VP of Sales & Marketing	350 HILLS STREET, SUITE 106, RICHLAND WA 99354
Michael W Mccormick	director	9923 EAST BELL ROAD, STE 130, SCOTTSDALE AZ 85260
William Cavanagh	officer: Vice President	350 HILLS STREET, SUITE 106, RICHLAND WA 99354
Philip J Vitale	director	8849 E. CALLE DE LAS BRISAS, SCOTTSDALE AZ 85255
Alan Hoffmann	director	3030 EAST CACTUS ROAD, SUITE 101, PHOENIX AZ 85032
Krista Cline	officer: Dir. of Operations, Secretary	350 HILLS STREET, STE 106, RICHLAND WA 99354
Jennifer Streeter	officer: VP of Human Resources	350 HILLS STREET SUITE 106, RICHLAND WA 99354